Clinical Trials Logo

Status Epilepticus clinical trials

View clinical trials related to Status Epilepticus.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06194747 Not yet recruiting - Status Epilepticus Clinical Trials

Improving Status Epilepticus Treatment Times

QuITT-SE
Start date: February 1, 2024
Phase: N/A
Study type: Interventional

This is a stepped-wedge cluster randomized effectiveness-implementation hybrid study aimed at determining the effect of dissemination of a QI bundle on the time to treatment of SE among hospitalized, non-critically ill children. The primary study endpoint is to decrease the time from the SE diagnosis to treatment with the first dose of a benzodiazepine (BZD) as measured during hospitalization, which will decrease chances of morbidity and mortality.

NCT ID: NCT06119919 Not yet recruiting - Clinical trials for Convulsive Status EPILEPTICUS

Cardiac Injury With Convulsive Status Epilepticus

Start date: January 1, 2024
Phase:
Study type: Observational

1. Determine the impact of cardiac injury on clinical profile, cardiac evaluation and outcome in patients hospitalized with convulsive status epilepticus (CSE). 2. Analyze the frequency of cardiac rhythm and conduction abnormalities related to seizures and determine risk factors and associated clinical characteristics. 3. Analyse ECG abnormalities and changes in HR in epileptic seizures since such disturbances might be a factor in SUDEP 4. Assessment of levels of cardiac enzymes in patients with status epilepticus

NCT ID: NCT06100978 Not yet recruiting - Clinical trials for Patient Satisfaction

Patient-reported Outcome and Patient-reported Experience After Status Epilepticus

POSEIDON2
Start date: March 1, 2024
Phase:
Study type: Observational

Status epilepticus (SE) is a common life-threatening neurological emergency in which prolonged or multiple closely spaced seizures can result in long-term impairments. SE remains associated with considerable mortality and morbidity, with little progress over the last three decades. The proportion of patients who die in the hospital is about 20% overall and 40% in patients with refractory SE. Morbidity is more difficult to evaluate, as adverse effects of SE are often difficult to differentiate from those attributed to the cause of SE. Our experience suggests that nearly 50% of patients may experience long-term functional impairments. The precise description of the consequences of these functional impairments and their impact on quality of life after SE requiring intensive care management has been little studied. Indeed, if cognitive, physical and mental impairments are now identified in the populations of patients who required intensive care under the term postresuscitation syndrome (PICS), neuronal lesions consecutive to the SE itselfor to its cause could be responsible for these different functional alterations. Thus, the following have been described: (i) cognitive disorders in the areas of attention, executive functions and verbal fluency, visual and working memory disorders, but also spatio-temporal disorders; (ii) physical disorders such as the so-called post-resuscitation polyneuromyopathy; and (iii) mental disorders such as anxiety disorders, depressive states or those related to post-traumatic stress. Assessment and characterization of patient-reported outcomes is essential to complement the holistic assessment of clinically relevant outcomes from the patient's perspective. The POSEIDON study was a cross-sectional collection of PROs and HR-QOL components, and associated with patient functional outcomes, in those who required ICU management for status epilepticus. We propose here to continue the description of potential alterations after a subsequent ME, namely a longitudinal study (POSEIDON 2) which will also include the evaluation of patient-reported experience (PREMS) and the measurement of family burden.

NCT ID: NCT05830864 Not yet recruiting - Clinical trials for Refractory Status Epilepticus

Multicenter Retrospective Study of Isoflurane in Refractory and Super-Refractory Status Epilepticus

I-Seizure
Start date: March 1, 2024
Phase:
Study type: Observational [Patient Registry]

Isoflurane might be used as anticonvulsive therapy in refractory status epilepticus. The aim of the study is to assess the efficiency of Isoflurane in this indication.

NCT ID: NCT05814523 Not yet recruiting - Clinical trials for Refractory Status Epilepticus

To Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus (RSE)

Start date: February 2024
Phase: Phase 3
Study type: Interventional

This is a multicenter, double-blind, randomized, placebo-controlled study that will evaluate the efficacy, safety, and tolerability of intravenous (IV) ganaxolone versus placebo co-administered with IV antiepileptic drug (AED) according to standard of care for the treatment of RSE. Approximately 70 participants will be randomized in a 1:1 ratio to receive ganaxolone IV solution or placebo IV solution along with standard of care (SOC) IV AED.

NCT ID: NCT05684978 Not yet recruiting - Clinical trials for Refractory Status Epilepticus

Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus

Start date: January 2, 2023
Phase: Phase 4
Study type: Interventional

This project is aiming to better understand the use of perampanel as an appropriate standard-of-care therapy for treatment refractory status epilepticus (RSE), to identify determinants of outcomes, and establish safety. The study will recruit 25 patients at WSU. The study will last for about 96 weeks and will involve a screening visit and two in clinic visits at 3 and 6 months. If the subjects give written informed consent and meet all eligibility criteria they will be clinically evaluated and will be given the study drug. This study will involve recording of patients medical history, drug history and epilepsy history. A physical exam and a and neurological exam will also be performed to study the heath status of the participant. Results and patient information will be stored in a database for analysis to find commonality among key factors that have been seen in past research.

NCT ID: NCT03251820 Not yet recruiting - Epilepsy Clinical Trials

Management Strategies For Electrical Status Epilepticus During Sleep

Start date: February 2018
Phase: N/A
Study type: Observational

Electrical status epilepticus during slow wave sleep is a condition in which the epileptic patient starts to develop neurocognitive deterioration, any type of seizures and continuous electrical activity in the EEG during non rapid eye movement sleep. It is an age related condition and will resolve spontaneously at around the age of puberty. However if left untreated or treatment is delayed, it may lead to permanent neurocognitive deterioration. Thus early diagnosis and treatment is essential in these children to preserve neurocognitive function.

NCT ID: NCT03245099 Not yet recruiting - Status Epilepticus Clinical Trials

Management of Non Convulsive Status Epilepticus

Start date: December 2017
Phase: N/A
Study type: Observational

Non convulsive status epilepticus is a persistent change in behavioural and or mental process from baseline associated with continuous epileptiform activity in electroencephalograph,it occur in about 50 percent in patients with coma and convulsions and in 8-13 percent in intensive care unit patients

NCT ID: NCT02344706 Not yet recruiting - Epilepsy Clinical Trials

Diagnostic Value of Prehospital EEG in Non-convulsive Status Epilepticus

Start date: December 1, 2018
Phase:
Study type: Observational

A large proportion of patients (up to 20%) who suffer from an epileptic seizure and remain unconscious suffer from a non-convulsive epileptic seizure. The condition is difficult to diagnose, and impossible without the required instruments. Electroencephalogram is required in the diagnosis of non-convulsive status epilepticus. Presently, the diagnostic value and implementation of such a device in the prehospital field is little studied. The aim of this study is to evaluate the diagnostic value of the acquired electroencephalogram with a prototype EEG/EKG adapter connected to a Physio-Control LifePak 15 defibrillator/monitor. The EEG is registered in a otherwise normal fashion with scalp-electrodes, but only three channels are monitored, as this is deemed sufficient for the prehospital field, as well as for monitoring the epileptic seizures.

NCT ID: NCT01268904 Not yet recruiting - Status Epilepticus Clinical Trials

Safety and Efficacy of Intravenous Valproate in Pediatric Status Epilepticus and Acute Repetitive Seizures

Start date: January 2011
Phase: N/A
Study type: Observational

To evaluate the safety and efficacy of intravenous valproate in pediatric status epilepticus and acute repetitive seizures as part of seizure treatment protocol in pediatric ER